Immunocore FY2025 EPS Forecast Boosted by Cantor Fitzgerald

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Immunocore in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($0.52) per share for the year, up from their previous estimate of ($1.42). The consensus estimate for Immunocore's current full-year earnings is ($0.94) per share.

Several other equities analysts have also issued reports on the stock. Mizuho cut their price objective on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Morgan Stanley reiterated an "equal weight" rating and issued a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. JPMorgan Chase & Co. reduced their price target on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price objective on shares of Immunocore in a research report on Wednesday, March 12th. Finally, Oppenheimer lifted their target price on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $58.13.

Immunocore Stock Down 3.0%

Shares of IMCR traded down $0.86 during mid-day trading on Monday, hitting $27.69. The company's stock had a trading volume of 352,501 shares, compared to its average volume of 428,853. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The company's 50-day moving average is $28.75 and its 200-day moving average is $30.10. Immunocore has a 52-week low of $23.15 and a 52-week high of $58.36. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -29.15 and a beta of 0.75.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.45. The company had revenue of $125.13 million for the quarter, compared to analysts' expectations of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm's quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.49) EPS.

Insider Activity at Immunocore

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 10.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Immunocore

Large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in Immunocore during the 4th quarter worth about $25,000. Oppenheimer Asset Management Inc. purchased a new position in shares of Immunocore in the first quarter worth about $225,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Immunocore by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC lifted its holdings in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after purchasing an additional 1,102 shares during the period. Finally, Tema Etfs LLC purchased a new stake in Immunocore in the fourth quarter valued at approximately $330,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.